
Valneva’s Single-Shot Chikungunya Vaccine Shows Promising Three-Year Antibody Persistence, Says New Report
Positive Antibody Persistence Data Reported for Valneva’s Chikungunya Vaccine Saint-Herblain (France), December 3, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine,…